NEW YORK (GenomeWeb News) – Biodesix said today it has entered a collaborative agreement with Bruker Daltonics to support its VeriStrat diagnostic test as well as future tests based on MALDI-TOF mass spectrometry.

A serum protein test for identifying non-small cell lung cancer patients likely to respond to various therapies, Veristrat runs on Biodesix's MALDI-TOF-based ProTS platform, which uses Bruker Autoflex and Ultraflextreme instruments.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.